Half-life and dosing frequency: why some peptides are daily and others weekly
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- A half-life is the time it takes for the level of a drug in the blood to fall by half. It largely decides how often a peptide has to be given.
- Natural peptides often last minutes. Approved drugs like semaglutide and tirzepatide were engineered, mainly by binding to albumin, to last about a week.
- Because semaglutide's half-life is about a week, its label says it stays in circulation for about 5 to 7 weeks after the last dose.
- Many research peptides have no human half-life data at all, so no schedule for them rests on a human measurement.
What a half-life is
A drug's half-life is the time it takes for its concentration in the blood to drop by half. After one half-life, half is left; after two, a quarter; after three, an eighth; after five, about 3%. The idea matters because it sets two practical things: how often a medicine has to be given to keep levels steady, and how long it lingers after the last dose. The Wegovy label shows both: semaglutide's elimination half-life is about one week, and the label says it will be present in the circulation for about 5 to 7 weeks after the last dose 1.
Half-life is measured in people under specific conditions, by a specific route. The same molecule can show different figures when injected into a vein or under the skin, because absorption from under the skin is slower. The Genotropin label gives a clear example: somatropin's mean terminal half-life is 0.4 hours given intravenously but 3.0 hours given under the skin, a difference the label puts down to slow absorption from the injection site 2.
Half-lives of common peptides
The table gathers half-lives from US drug labels, plus one research peptide with a human study. Our Half-Life Visualizer plots these curves over time.
| Peptide (product) | Half-life | Usual schedule | Source |
|---|---|---|---|
| Native GLP-1 | 1.5 to 2 minutes | (made by the body) | Saxenda label |
| Tesamorelin (EGRIFTA WR) | 11 minutes | Daily | Label |
| Bremelanotide (Vyleesi) | About 2.7 hours | As needed, before sex | Label |
| Exenatide (Byetta) | 2.4 hours | Twice daily | Label |
| Somatropin (Genotropin), under the skin | 3.0 hours | Daily | Label |
| Liraglutide (Saxenda) | 13 hours | Daily | Label |
| Lonapegsomatropin (Skytrofa) | About 25 to 31 hours | Weekly | Label |
| Tirzepatide (Zepbound) | About 5 to 6 days | Weekly | Label |
| Semaglutide (Wegovy) | About 1 week | Weekly | Label |
| CJC-1295 with DAC (research) | 5.8 to 8.1 days | Not approved | 2006 human study |
From minutes to a week: how peptides are made to last
The body's own GLP-1 acts briefly. The Saxenda label explains that natural GLP-1 has a half-life of only 1.5 to 2 minutes because enzymes called DPP-4 and neutral endopeptidases break it down quickly; liraglutide resists both and has a plasma half-life of 13 hours, suitable for once-daily dosing 3. Exenatide, cleared by the kidneys, lasts 2.4 hours and is given twice a day 4.
The weekly drugs go further by hitching a ride on albumin, the most abundant protein in blood. The Wegovy label says semaglutide's main protraction mechanism is albumin binding, made possible by a fatty acid chain attached to the peptide; it is more than 99% bound to albumin, which reduces clearance by the kidneys and protects it from degradation 1. Tirzepatide uses the same trick: its label says it contains a C20 fatty diacid that enables albumin binding and prolongs the half-life, giving about 5 to 6 days 5.
Growth hormone shows another approach. Daily somatropin under the skin has a half-life of about 3 hours 2; Skytrofa, a weekly form, releases somatropin from a carrier so that the somatropin it releases has an apparent half-life of about 25 hours 6. For CJC-1295 with DAC, a research peptide, the half-life in healthy adults was estimated at 5.8 to 8.1 days (human study) 7.
Short-acting peptides and why they are used anyway
A short half-life is not a flaw for every purpose. Tesamorelin has a mean elimination half-life of 11 minutes in healthy subjects after a single injection under the skin, yet its label doses it once daily; it acts on the receptors for the body's own growth-hormone-releasing factor, so its purpose is to prompt the body's own growth hormone release rather than to stay in the blood 8. Bremelanotide (Vyleesi), with a half-life of about 2.7 hours, is meant to be used on demand before sex, not to keep a steady level 9. Ipamorelin, a research peptide, had a terminal half-life of about two hours when infused into a vein in healthy men, and each dose produced a single episode of growth hormone release (human study) 10.
So half-life is only half the story. What matters is how long the effect lasts and whether the goal is a steady level or a pulse.
Steady state, build-up and wash-out
When a drug is given repeatedly at intervals shorter than the time it takes to clear, levels build up until intake and clearance balance, a point called steady state. A long half-life also means the drug lingers: the Wegovy label links its 5 to 7 weeks in the circulation after the last dose to the one-week half-life 1. The Zepbound label, for the same reason, says observation after an overdose may need to account for tirzepatide's half-life of about 5 days 5.
The labels for weekly drugs also start low and step the dose up over weeks; the Wegovy label says to follow its escalation schedule to reduce the risk of gastrointestinal adverse reactions 1. Our Split-Dose Simulator shows how splitting the same weekly amount into smaller, more frequent doses changes the peaks and troughs; it illustrates the principle and is not dosing advice.
Terminal, apparent, elimination: reading the labels
Labels use slightly different terms, and they are worth knowing. An elimination or terminal half-life describes the final, slowest phase of clearance, after the drug has spread through the body; the Vyleesi label, for example, gives bremelanotide's mean terminal half-life as about 2.7 hours, with a range of 1.9 to 4.0 hours across people 9. An apparent half-life is what is observed when absorption or release is slower than elimination, so the slow step sets the pace: the Skytrofa label reports an observed half-life of 30.7 hours for the carrier-bound drug, and an apparent half-life of about 25 hours for the somatropin it releases 6. The Genotropin label's two figures, 0.4 hours intravenously and 3.0 hours under the skin, show the same effect from slow absorption 2.
The ranges matter. A half-life is an average, and people differ. A single number on a chart is a guide, not a promise about any individual, and it says nothing about how strongly the drug acts while it is there.
How the body clears peptides
The Byetta label says nonclinical studies show exenatide is predominantly eliminated by glomerular filtration, the kidneys' filtering, followed by breakdown 4; in rats and dogs, BPC-157 was broken into small fragments and then single amino acids (animal study) 11. Albumin binding is what slows that down for semaglutide, by reducing clearance through the kidneys 1. Whether kidney or liver problems change a peptide's levels has to be tested for each drug. For cagrilintide, single doses produced similar exposure in people with different degrees of kidney or liver function, with no consistent pattern by impairment (human study by Novo Nordisk, the drug's developer) 12. Those findings do not transfer automatically to other peptides.
Half-life and missed doses
Long half-lives also explain the generous windows for missed doses on weekly drugs. The Zepbound label says a missed dose can be taken within 4 days; after that, it should be skipped and the next dose taken on schedule 5. Our travel guide uses these windows to plan doses around time zones.
Research peptides: mostly unknown
For many peptides sold online, no human half-life has been measured. BPC-157 is a good example: a 2022 study in rats and beagle dogs found its elimination half-life was under 30 minutes after injection, with the intact peptide quickly broken down into small fragments, and bioavailability after intramuscular injection of about 14% to 19% in rats and 45% to 51% in dogs (animal study) 11. A PubMed search on October 27, 2026 found no human pharmacokinetic study of BPC-157, so any daily or twice-daily schedule for it is not based on human measurements.
Names can mislead too. The 5.8-to-8.1-day half-life was measured for the CJC-1295 tested in that study 7; it does not apply to products sold as CJC-1295 "without DAC", for which that study gives no figure. Our CJC-1295 and ipamorelin page explains the difference.
Natural hormones are short for a reason
Many of the body's own peptide hormones last minutes. Oxyntomodulin, a gut hormone, had a half-life of about 12 minutes in plasma during infusion in six volunteers (human study) 13, and native GLP-1 lasts 1.5 to 2 minutes 3. Drugs acting on the same receptor can differ widely: liraglutide's 13-hour half-life suits a daily injection 3, and semaglutide's one-week half-life a weekly one 1.
Questions to ask about any peptide's schedule
- Is the half-life measured in people, and by the route I would use?
- Is the goal a steady level or a short pulse?
- How long would the drug and its side effects linger after stopping?
- For a research peptide, is there any human pharmacokinetic study at all?
The bottom line
Half-life explains why semaglutide is weekly and exenatide twice daily: the weekly drugs are engineered to bind albumin and resist breakdown. It also explains why a weekly drug lingers for weeks after the last dose. For approved peptides, the label gives the number; for most research peptides, nobody has measured it in people.
Frequently asked questions
What is the half-life of semaglutide?
About one week, according to the Wegovy label, which says semaglutide stays in the circulation for about 5 to 7 weeks after the last dose.
What is the half-life of tirzepatide?
About 5 to 6 days in people with overweight or obesity, according to the Zepbound label.
Why are some peptides taken weekly?
Drugs like semaglutide and tirzepatide carry a fatty acid chain that binds them to albumin in the blood, slowing their clearance and breakdown so that one injection lasts about a week.
How long does BPC-157 stay in your system?
No human pharmacokinetic study was found on PubMed. In rats and dogs, its half-life was under 30 minutes, and it was quickly broken into small fragments.
Does a short half-life mean a peptide doesn't work?
No. Tesamorelin has an 11-minute half-life but its label doses it once daily; it acts by prompting the body's own growth hormone release.
Related on Grey Peptides
Sources
- Novo Nordisk. WEGOVY (semaglutide) US prescribing information, sections 10, 11 and 12.3. DailyMed version 19, effective June 18, 2026; read October 3, 2026. DailyMed
- Pfizer. GENOTROPIN (somatropin) US prescribing information, section 12.3. DailyMed version 37; read October 3, 2026. DailyMed
- Novo Nordisk. SAXENDA (liraglutide) US prescribing information, sections 12.1 and 12.3. DailyMed version 22; read October 3, 2026. DailyMed
- AstraZeneca. BYETTA (exenatide) US prescribing information, section 12.3. DailyMed version 26; read October 3, 2026. DailyMed
- Eli Lilly. ZEPBOUND (tirzepatide) US prescribing information, sections 10, 12.1 and 12.3. DailyMed version 40, effective August 28, 2026; read October 3, 2026. DailyMed
- Ascendis Pharma. SKYTROFA (lonapegsomatropin-tcgd) US prescribing information, section 12.3. DailyMed version 14, effective October 21, 2026; read October 27, 2026 (section 12.3 unchanged since it was first read on October 3, 2026). DailyMed
- Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805. PMID: 16352683
- Theratechnologies. EGRIFTA WR (tesamorelin) US prescribing information, section 12.3. DailyMed version 2; read October 3, 2026. DailyMed
- Cosette Pharmaceuticals. VYLEESI (bremelanotide injection) US prescribing information, section 12.3. DailyMed version 1; read October 3, 2026. DailyMed
- Gobburu, J. V., et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res, 16(9), 1412-6. PMID: 10496658
- He, L., et al. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol, 13, 1026182. PMID: 36588717
- Nielsen, M. J. F., et al. (2026). Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clin Pharmacokinet, 65(7), 1087-1099. PMID: 42228334
- Schjoldager, B. T., et al. (1988). Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest, 18(5), 499-503. PMID: 3147901
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead